Genprex

Monthly Archives: November 2019

Genprex Announces $1.26 Million Registered Direct Offering

The company announced a registered direct offering of 3,167,986 shares of its common stock at a price to the public of $0.40 per share, for gross proceeds of approximately $1.26 million prior to deduction of commissions and offering expenses payable by Genprex.

Read More

Genprex Reports Positive Preclinical Data for the Treatment of Some of the Most Resistant Metastatic Lung Cancers

The company announced a registered direct offering of 3,167,986 shares of its common stock at a price to the public of $0.40 per share, for gross proceeds of approximately $1.26 million prior to deduction of commissions and offering expenses payable by Genprex.

Read More

Genprex Issues Lung Cancer Prevention Measures in Support of Lung Cancer Awareness Month

AUSTIN, Texas & CAMBRIDGE, Mass.— (November 4, 2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage gene therapy company, is publishing lung cancer prevention measures in an effort to educate the public, prevent new cases and raise awareness of lung cancer while supporting November’s Lung Cancer Awareness Month.

Each patient’s cancer is unique, but there are some preventive efforts that can be made to lower the risk of getting lung cancer….

Read More